Brokerages Set Establishment Labs Holdings Inc. (NASDAQ:ESTA) Target Price at $56.50

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have been given a consensus rating of “Moderate Buy” by the six brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $56.50.

Several analysts have recently weighed in on the stock. Canaccord Genuity Group assumed coverage on shares of Establishment Labs in a research report on Wednesday, August 20th. They set a “buy” rating and a $60.00 price objective for the company. Mizuho lifted their target price on shares of Establishment Labs from $58.00 to $70.00 and gave the company an “outperform” rating in a report on Wednesday, July 16th. Needham & Company LLC reissued a “buy” rating and issued a $48.00 price objective on shares of Establishment Labs in a research note on Friday, June 13th. Wall Street Zen cut shares of Establishment Labs from a “hold” rating to a “sell” rating in a research note on Saturday, August 16th. Finally, Citigroup upped their price target on shares of Establishment Labs from $38.00 to $47.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 9th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd purchased a new position in Establishment Labs in the 1st quarter valued at about $81,000. Osaic Holdings Inc. grew its position in Establishment Labs by 900.0% in the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after acquiring an additional 1,800 shares in the last quarter. CWM LLC grew its position in Establishment Labs by 45.9% in the second quarter. CWM LLC now owns 2,182 shares of the company’s stock valued at $93,000 after acquiring an additional 686 shares in the last quarter. Elevation Point Wealth Partners LLC acquired a new stake in shares of Establishment Labs during the first quarter worth approximately $207,000. Finally, Patriot Financial Group Insurance Agency LLC acquired a new stake in shares of Establishment Labs during the first quarter worth approximately $234,000. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

Establishment Labs Trading Down 1.7%

NASDAQ ESTA opened at $36.84 on Thursday. Establishment Labs has a one year low of $26.56 and a one year high of $50.85. The firm has a 50 day simple moving average of $40.67 and a 200-day simple moving average of $37.94. The company has a debt-to-equity ratio of 9.71, a quick ratio of 1.67 and a current ratio of 2.84. The firm has a market cap of $1.07 billion, a price-to-earnings ratio of -12.08 and a beta of 0.85.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.03). Establishment Labs had a negative return on equity of 224.34% and a negative net margin of 49.89%.The firm had revenue of $51.30 million during the quarter, compared to analysts’ expectations of $50.80 million. During the same quarter in the prior year, the firm earned ($0.62) EPS. The firm’s revenue was up 16.1% compared to the same quarter last year. Establishment Labs has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Establishment Labs will post -2.41 EPS for the current fiscal year.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.